These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 17325666)

  • 1. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
    Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
    Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.
    Wu YH; Wu TC; Liao JW; Yeh KT; Chen CY; Lee H
    Cancer Res; 2010 Dec; 70(24):10422-32. PubMed ID: 21056989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
    Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
    Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
    J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.
    Qiu W; Zhou B; Zou H; Liu X; Chu PG; Lopez R; Shih J; Chung C; Yen Y
    Am J Pathol; 2004 Nov; 165(5):1689-99. PubMed ID: 15509538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
    Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
    Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
    Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
    Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
    Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
    Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers.
    Kersting M; Friedl C; Kraus A; Behn M; Pankow W; Schuermann M
    J Clin Oncol; 2000 Sep; 18(18):3221-9. PubMed ID: 10986054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
    Shao G; Berenguer J; Borczuk AC; Powell CA; Hei TK; Zhao Y
    Cancer Res; 2006 May; 66(9):4566-73. PubMed ID: 16651406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
    Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
    Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR
    Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
    Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
    Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma.
    Oue N; Shigeishi H; Kuniyasu H; Yokozaki H; Kuraoka K; Ito R; Yasui W
    Int J Cancer; 2001 Sep; 93(6):805-9. PubMed ID: 11519041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
    Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
    Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
    Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.